Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. - Wikidata - awgldk - TriplyDB

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

http://www.wikidata.org/entity/Q34744555

about

Targeting the CCL2-CCR2 signaling axis in cancer metastasis Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Biomarkers for glioma immunotherapy: the next generation CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages Targeting tumor-associated macrophages to combat pancreatic cancer Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.CCL2-expressing astrocytes mediate the extravasation of T lymphocytes in the brain. Evidence from patients with glioma and experimental models in vivo.Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model.Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS)Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Tyrosine receptor kinase B is a drug target in astrocytomas.Impact of temozolomide on immune response during malignant glioma chemotherapy Profound impairment of adaptive immune responses by alkylating chemotherapy Premetastatic soil and prevention of breast cancer brain metastasis The significance of macrophage phenotype in cancer and biomaterials.KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.Targeting tumor-infiltrating macrophages to combat cancer.Immune-checkpoint blockade and active immunotherapy for glioma.Aptamer identification of brain tumor-initiating cells.Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.Anti-tumour strategies aiming to target tumour-associated macrophages.Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies.Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.Myeloid-derived suppressor cells in glioma.Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Vaccine adjuvant uses of poly-IC and derivatives.Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.Ingramon, a Peptide Inhibitor of MCP-1 Chemokine, Reduces Migration of Blood Monocytes Stimulated by Glioma-Conditioned Medium.Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma.Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.Immunological effects of chemotherapy and radiotherapy against brain tumors.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Tumor-Associated Macrophages as Target for Antitumor Therapy.Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts.

P2860

Q26765184-9BB67C03-0BF7-4766-9B36-C9DADA681B36 Q26798402-FEC39A24-702E-4057-A9BD-D68CC472E0A4 Q26825496-E2AAC9F9-440D-41F8-B1AE-4DAA42189FD6 Q27308841-93420737-B3B2-4D02-84DB-08A0E9975337 Q28076103-DB35EE86-CDDC-4792-89FB-4517B28698EA Q33670136-32034485-2C62-4F5F-9127-14F746ED7BBF Q34154663-44DDFE74-9E09-440A-88F7-A00CDCE672E1 Q34198939-C8B130D8-898B-434D-B75C-ED34E073F423 Q34364876-EECE5BFF-9EBC-4C80-A8DB-81B0C113BCFC Q35056718-19125729-7E02-4FFB-9736-DC39636B7802 Q35080064-949585E8-58B3-414F-AE49-7B6703860F20 Q35580479-F8BD970E-46C2-4336-B7A2-53D31002D40F Q36073551-5ABACF2F-2137-4AEF-8B97-21C2E56A5C7E Q36362798-2ACACE10-9BB4-4DAF-9A0E-FAA9F9C829F5 Q36922577-069810EE-9501-43BD-9F60-A9829085C484 Q36943888-521D3779-1B90-459D-A5E1-690AEF21EDEC Q36944484-AE4D53D1-9086-4783-AAD7-6C8BE160E137 Q37327602-093E3144-3980-43DD-90A9-6D4CFAB4C20F Q37401717-7425BAAC-7311-4E01-95D7-B3A177A38037 Q37420586-3D0318D0-5791-4B39-B95C-440CBABD73AD Q37601425-9F2795CB-5234-4EB3-9142-51908751E9CD Q37608572-CFEC7001-25AB-439C-B418-5B73B2BAA656 Q37647868-144D9353-010D-45EB-A731-853E7A869462 Q38047053-54E70C9F-2F06-4D47-8A92-3D9955A15ECA Q38056746-BD1853CB-F3B3-4426-8344-9A32BF1C1CD3 Q38122365-3F82436B-F46A-40E7-9DAE-68082D289F24 Q38154151-09C4F1A5-CE6E-4594-9206-5F77310ABB66 Q38161536-69EC5056-190C-4BBB-B228-6194F110A8FE Q38227496-A72D47A9-582F-41E3-B91C-A2A2AE94675F Q38227889-EA515871-3584-4953-BF76-29E3465D6046 Q38259510-3C299A4C-AFF6-4514-A422-FB9D1ABBE288 Q38637324-B616E957-3EF1-4498-BEF7-7E434433EAFA Q38726039-120A0F4F-76CD-4FDF-A37A-008D8DDE043B Q38791716-7F22DD1B-D0C6-4110-877B-871E0BF81436 Q38861364-0F52B0B5-1A35-4B4E-BD15-A13297E83B53 Q38925761-E8EB5B01-D135-40C1-9517-61BE6CF91FA9 Q38947116-E0C8BA96-34FC-4C8A-A2C9-FE0769E9864B Q38989773-97F44DDD-0EB8-42CF-B7E8-634098ADDFB9 Q39403895-B073E0B7-2030-44C8-B14D-869DF20AD97D Q40124047-41316029-5A2B-4261-8196-A24D6C9E1964

P2860

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

http://www.wikidata.org/entity/Q34744555

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@ast

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@en

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@nl

type

label

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@ast

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@en

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@nl

prefLabel

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@ast

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@en

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@nl

P1433

Q34744555-CC9EF8E2-4A43-46D0-9242-4C27C4A0A852

P1476

Q34744555-45AFA79A-D1DF-49B4-8A7F-41F29C76C4C4

P2093

Q34744555-0165A655-F9C2-46EC-BA05-55662250DACA

Q34744555-9FD6BF2D-9DF1-4856-A439-1450B335E030

Q34744555-A1FB0599-54BE-40C0-8F20-866F0EDD7E31

Q34744555-E61CF8B0-299F-4467-93B0-7597BB254C3B

P2860

Q34744555-0638CBD7-A4D4-412D-8037-106681A51C96

Q34744555-21AB7231-28CA-44C1-A90A-B1047F207C8A

Q34744555-254D840A-6A64-4868-A243-0448A0EFC017

Q34744555-3184AB0D-0D11-4E7E-AA13-B844A4D7D400

Q34744555-37E218AE-0C21-4309-89A7-7507FA12BC63

Q34744555-566EA401-73B5-4E19-8C14-4294C9B5CD32

Q34744555-680247D1-70F2-455F-B558-09860C273757

Q34744555-725E4B05-9F3E-4B6F-9B64-0976ECEC1C8E

Q34744555-7834B57E-2BED-474F-893D-578A0E1DCC8A

Q34744555-78432529-27AA-4781-A709-CD5BF7435136

P2888

Q34744555-A84C3C84-3550-4088-9FBE-114987479701

P304

Q34744555-9E4DFDF1-3487-4EE3-B698-EBA7AFEAA7CF

P31

Q34744555-D80B96AD-648D-43A2-95E3-712B6995E172

P356

Q34744555-F8545EE6-1E2E-4048-8331-FE4D1C599E84

P433

Q34744555-643D8E1A-D283-4C58-BB30-32E8A5C548C9

P478

Q34744555-21529776-9F71-41F5-85CA-E885D0A9F4F4

P577

Q34744555-64C0CD31-541B-4C1E-9BEA-9ADBFB98542B

P5875

Q34744555-FC833D90-0183-47A7-8E32-E62232C86C97

P6179

Q34744555-EE63204C-56E7-48BD-A79D-7F97C0366BAD

P698

Q34744555-A1EC5D7E-D3AD-4515-ABCD-BE8A2EB69618

P921

Q34744555-851880C4-A6A9-46D8-B1D8-16BE84FE2524

P932

Q34744555-9EBE4C65-F5FD-48E4-A585-2C2924868A2F

P356

S11060-010-0473-5

P1433

Journal of Neuro-Oncology

P1476

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

@en

P2093

Hideho Okada

http://www.w3.org/2001/XMLSchema#string

Linda A Snyder

http://www.w3.org/2001/XMLSchema#string

Mitsugu Fujita

http://www.w3.org/2001/XMLSchema#string

Xinmei Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Myeloid-derived suppressor cells as regulators of the immune system

Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

Codon engineering for improved antibody expression in mammalian cells.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

CCL2 blockade augments cancer immunotherapy.

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners

P2888

s11060-010-0473-5

P304

83-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-010-0473-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49644471

http://www.w3.org/2001/XMLSchema#string

P6179

1040053762

http://www.w3.org/2001/XMLSchema#string

P698

21116835

http://www.w3.org/2001/XMLSchema#string

P921

P932

3068234

http://www.w3.org/2001/XMLSchema#string